The Veterans Administration and Department of Defense issue a clinical practice guideline regarding opioid therapy for chronic pain in veterans.
Conditions such as chronic disease, mental illness, or substance abuse commonly overlap with each other and with poverty, which contributes to poor health.
Developments in functional, structural, and neurochemical imaging could help predict individuals with acute pain who are likely to progress to chronic pain.
Prepubertal children who regularly engage in sedentary behavior have an increased likelihood of experiencing various pain conditions.
Pain management specialists may have an important role to play in the treatment of patients with chronic visceral pain.
Acceptance and commitment therapy can have positive outcomes in adults with chronic pain.
Young adults with sleep problems have increased risks of developing chronic pain and experiencing worsening in pain severity.
The CDC's new guideline regarding opioid therapy for chronic pain focuses on balancing potential benefits and harms to the patient.
Patient monitoring and pain specialist support can help primary care practitioners better manage their patients taking opioids for chronic pain.
According to a study in the Journal of Pain, nearly 50 million adults in the United States live with chronic significant or severe pain.
Naloxegol functions as a peripherally acting mu-opioid receptor antagonist in tissues such as the gastrointestinal tract, thereby decreasing the constipating effects of opioids.
Chronic pain and depression symptoms are common among patients with HIV.
A significant number of pain patients who use alternative therapies have not discussed them with their clinicians.
Researchers have developed a way to determine back pain patients' risk for chronic pain.
Some HIV-positive patients may be employing harmful self-management strategies to cope with chronic pain.
The benefits of CranioSacral Therapy may not outweigh the intensive training and medical costs associated with the treatment.
Hydrocodone bitartrate is difficult to crush, break, or dissolve, making it resistant to abuse.
Compared with patients without chronic pain, opioid users had higher risks of injuries and toxicity/poisoning resulting in hospital inpatient admissions.
An obese patient with chronic hepatitis C, diabetes, advanced cirrhosis, and fatty pancreas presents with chronic right-to-middle upper-abdomen pain.
Due to the limited amount of high-quality human studies, craniosacral therapy should not be suggested as a first-line treatment.
Identifying and modifying risk factors through engaging in preventative health activities is the key to achieving good health from head to toe, and is the backbone of primary care.
Failure to properly treat patients suffering legitimate chronic pain syndromes can result in a compounding of prescription pain-medication abuse.
Just 8% of participants in a study assessing how primary care patients who are prescribed opioids are tracked underwent urine testing, only half made regular visits to their prescribers and 23% received more than one early opioid refill.
Two large studies have underscored the benefits of yoga for people suffering from low back pain.
Pain is the one concern that more often than not prompts people to see a health-care provider, so adequately addressing these complaints can significantly influence the relationship you have with your patients.
Assessment of functional impairments in an aging population is one of the most daunting challenges facing primary-care clinicians.
Although Fibromyalgia is one of the most prevalent chronic pain diagnoses in the United States, no single laboratory or physical exam will help clinicians identify the disorder, a speaker told audiences at the American Academy of Nurse Practitioners 26th Annual NP meeting.
A drastic shift in prescribing patterns is increasing the magnitude of opioid abuse in the United States.
Researchers at the American Pain Society's 30th Annual Scientific Meeting discussed data from a review of spontaneous adverse events reported with Embeda (morphine sulfate and naltrexone HCl) treatment, with a focus on events potentially related to product tampering.
Fulranumab no more efficacious than placebo for treating patients with chronic low back pain.